BEST ADD-ON THERAPY GIVING EFFECTIVE RESPONSES (BADGER)

这个子项目是众多研究子项目之一

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Monotherapy with inhaled corticosteroid (ICS) in mild to moderate persistent asthma in children has been shown to be beneficial in most children. The natural next step in studying asthma therapy options is determining the optimal add-on medication (increasing ICS, LABA or LTRA) to ICS when monotherapy with ICS at that dose is inadequate to control asthma satisfactorily. BADGER, or Best Add-on Therapy Giving Effective Responses, will answer the question about best add-on medication in 180 children (36 per clinical center) who have a history of mild to moderate asthma and are not completely controlled on low dose ICS. The study design is a triple cross over with each child receiving each add-on medication. The primary outcomes will be treatment response based on asthma exacerbation, asthma control days, and change in forced expiratory volume in one second (lung function testing).